Zydus Lifesciences Limited — Carvedilol Exporter Profile
Indian Pharmaceutical Exporter · #1 for Carvedilol · $21.9M export value · DGFT Verified
Zydus Lifesciences Limited is the #1 Indian exporter of Carvedilol with $21.9M in export value and 656 verified shipments. Zydus Lifesciences Limited holds a 22.3% market share in Carvedilol exports across 4 countries. The company exports 81 pharmaceutical products worth $346.3M across 25 therapeutic categories.
Zydus Lifesciences Limited — Carvedilol Export Profile: Buyers & Destinations
Where Does Zydus Lifesciences Limited Export Carvedilol?
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $15.6M | 594 | 94.4% |
| SRI LANKA | $595.9K | 49 | 3.6% |
| BRAZIL | $312.7K | 12 | 1.9% |
| KENYA | $9.6K | 1 | 0.1% |
Zydus Lifesciences Limited exports Carvedilol to 4 countries. The largest destination is UNITED STATES accounting for 94.4% of Zydus Lifesciences Limited's Carvedilol shipments, followed by SRI LANKA (3.6%) and BRAZIL (1.9%). These destinations reflect Zydus Lifesciences Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Carvedilol from Zydus Lifesciences Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| EVERSANA LIFE SCIENCE SERVICES | UNITED STATES | $11.4M | 436 |
| AMERISOURCE HEALTH SERVICES, | UNITED STATES | $3.2M | 129 |
| PRIORITY HEALTHCARE DISTRIBUTION | UNITED STATES | $553.2K | 17 |
| SUNSHINE HEALTHCARE LANKA LIMITED | SRI LANKA | $311.9K | 36 |
| STATE PHARMACEUTICALS | SRI LANKA | $280.8K | 12 |
| AMERISOURCE HEALTH SERVICES | UNITED STATES | $239.5K | 9 |
| ZYDUS NIKKHO FARMACEUTICA LTDA | BRAZIL | $162.7K | 9 |
| ZYDUS NIKKHO FARMACEUTICA LTDA. | BRAZIL | $150.0K | 3 |
| PRIORITY HEALTHCARE DISTRIBUTION DB | UNITED STATES | $110.6K | 3 |
| ABACUS PHARMA (AFRICA) LTD | KENYA | $9.6K | 1 |
Zydus Lifesciences Limited supplies Carvedilol to 11 buyers globally. The largest buyer is EVERSANA LIFE SCIENCE SERVICES (UNITED STATES), followed by AMERISOURCE HEALTH SERVICES, (UNITED STATES) and PRIORITY HEALTHCARE DISTRIBUTION (UNITED STATES). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Carvedilol Export Value and How Much Does Zydus Lifesciences Limited Contribute?
India exported $67.1M worth of Carvedilol through 4,750 shipments from 242 suppliers to 98 countries, serving 529 buyers globally. Zydus Lifesciences Limited contributes $21.9M to this total, accounting for 22.3% of India's Carvedilol exports. Zydus Lifesciences Limited ships Carvedilol to 4 countries through 11 buyers.
What Is the Average Shipment Value for Zydus Lifesciences Limited's Carvedilol Exports?
Zydus Lifesciences Limited's average Carvedilol shipment value is $33.4K per consignment, based on 656 shipments totaling $21.9M. The largest destination is UNITED STATES (94.4% of Zydus Lifesciences Limited's Carvedilol exports).
How Does Zydus Lifesciences Limited Compare to Other Indian Carvedilol Exporters?
Zydus Lifesciences Limited ranks #1 among 242 Indian Carvedilol exporters with a 22.3% market share. The top 3 exporters are ZYDUS LIFESCIENCES LIMITED ($21.9M), GLENMARK PHARMACEUTICALS LIMITED ($8.4M), AUROBINDO PHARMA LTD ($7.6M). Zydus Lifesciences Limited processed 656 shipments to 4 destination countries.
What Carvedilol Formulations Does Zydus Lifesciences Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| PHARMA MEDICINE FOR HUMAN USE-CARVEDILOL 12.5MG TABS 1X500-QTY-39,024.000 PAC-AS PER INVNOS | $269.4K | 6 |
| CARVEDILOL 25MG TABLETS [1X500 PER PACK] | $186.3K | 5 |
| PHARMA MEDICINE FOR HUMAN USE-CARVEDILOL 6.25MG TABS 1X500 -QTY-30,504.000 PAC-AS PER INVNOS | $164.2K | 6 |
| PHARMA MEDICINE FOR HUMAN USE-CARVEDILOL12.5MG TABS 1X500-QTY-68208.000 PAC-ASPER INVNOS | $150.0K | 3 |
| PHARMA MEDICINE FOR HUMAN USE-CARVEDILOL 25MG TABS 1X500-QTY-29004.000-PAC-ASPER INVNOS | $150.0K | 3 |
| CARVEDILOL TAB USP 25 MG-1X500 NDC-6800115203,B.N.Z401602 TO Z401606,Z401618 TO Z401620,MFD-03/24,EXP-02/26 | $150.0K | 3 |
| CARVEDILOL 12.5MG TABS 1X500 (OTHER DETAILS AS PER INV & P.LIST) | $150.0K | 3 |
| PHARMACEUTICALS MEDICINE FOR HUMAN USE-CARVEDILOL 25MG TABS 1X500-QTY-24,384.000PAC-AS PER INVOICE | $139.5K | 3 |
| CARVEDILOL 12 5MG TABLET 1 X 500 OTHERDETAILS AS PER INV AND PLIST | $134.9K | 3 |
| PHARMA MEDICINE FOR HUMAN USE-CARVEDILOL25MG TABS 1X500-QTY-19,476.000-PAC | $125.5K | 3 |
Zydus Lifesciences Limited exports 415 distinct Carvedilol formulations including tablets, capsules, syrups, and combination drugs. The top formulation is PHARMA MEDICINE FOR HUMAN USE-CARVEDILOL 12.5MG TABS 1X500- with 6 shipments worth $269.4K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
Regulatory Requirements: Exporting Carvedilol to Key Markets
What Zydus Lifesciences Limited must comply with to export Carvedilol to its top destination countries
United States — FDA
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Brazil — ANVISA
Approval Process
Generic registration under RDC 200/2017. ANVISA GMP inspection of Indian facility mandatory before approval.
Timeline: 12–24 months
GMP & Export Requirements
ANVISA GMP certificate (CBPF) for each manufacturing site; on-site inspection by ANVISA
Certificate of Pharmaceutical Product from CDSCO; Import Authorization via SISCOMEX
Note: ANVISA maintains active Indian pharma facility inspection program. Inspection backlog can extend timelines.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Zydus Lifesciences Limited Compare to Nearest Carvedilol Exporters?
Exporters ranked immediately above and below #1 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | ZYDUS LIFESCIENCES LIMITED ★ | $21.9M | 656 | 4 | $33.4K |
| 4 | GLENMARK PHARMACEUTICALS LIMITED | $8.4M | 257 | 2 | $32.7K |
| 5 | AUROBINDO PHARMA LTD | $7.6M | 484 | 15 | $15.7K |
Zydus Lifesciences Limited ranks #1 among 242 Indian Carvedilol exporters. Average shipment value of $33.4K compared to the market average of $277.3K. The closest competitors by value are GLENMARK PHARMACEUTICALS LIMITED and AUROBINDO PHARMA LTD.
Which Indian Ports Ship Carvedilol Exports?
| Port | Shipments | % Share |
|---|---|---|
| NHAVA SHEVA SEA (INNSA1) | 506 | 10.7% |
| SAHAR AIR | 482 | 10.1% |
| DELHI AIR CARGO ACC (INDEL4) | 405 | 8.5% |
| SAHAR AIR CARGO ACC (INBOM4) | 358 | 7.5% |
| MUNDRA SEA | 305 | 6.4% |
| DELHI AIR | 288 | 6.1% |
| HYDERABAD ICD (INSNF6) | 253 | 5.3% |
| JNPT/ NHAVA SHEVA SEA | 238 | 5.0% |
What Other Cardiovascular Products Does Zydus Lifesciences Limited Export?
Zydus Lifesciences Limited also exports these cardiovascular products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Zydus Lifesciences Limited's Carvedilol Exports
Zydus Lifesciences's export operations are influenced by various geopolitical factors. The Israel-Iran tensions have led to disruptions in Red Sea shipping routes, increasing shipping costs and transit times for Indian exporters. This situation necessitates strategic logistics planning to mitigate potential delays and cost escalations.
Conversely, U.S.-China trade tensions have opened opportunities for Indian pharmaceutical companies like Zydus to capture a larger share of the U.S. market, as American importers seek alternative suppliers. Zydus's recent FDA approvals, including Niacin ER Tablets and Leuprolide Acetate injection, position the company to capitalize on this shift. (ainvest.com)
In the European Union, compliance with the Falsified Medicines Directive (FMD) is crucial for market access. Zydus's proactive measures to align with these regulations enhance its credibility and competitiveness in the EU market. However, the ongoing Israel-Iran conflict poses risks to Middle East trade routes, potentially affecting Zydus's operations in that region.
Zydus Lifesciences Limited — Regulatory Compliance & Quality Standards
Maintaining stringent quality standards is paramount for Zydus Lifesciences. In October 2025, the company received an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) status from the U.S. FDA for its Baddi manufacturing facility, indicating compliance with regulatory standards. (bajajbroking.in) Similarly, the Ahmedabad SEZ-II facility received a clean USFDA report in November 2025, further affirming the company's commitment to quality. (bajajbroking.in)
These regulatory approvals are critical, as non-compliance can lead to import bans and reputational damage. Zydus's adherence to Good Manufacturing Practices (GMP) and proactive engagement with regulatory bodies underscore its dedication to maintaining high-quality standards across its operations.
About Zydus Lifesciences Limited
Zydus Lifesciences Limited exports 81 products worth $346.3M. Beyond Carvedilol, top products include Losartan, Iron, Mesalamine, Omeprazole, Potassium. View the complete Zydus Lifesciences Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Carvedilol — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Carvedilol shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Zydus Lifesciences Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 656 individual customs records matching Zydus Lifesciences Limited exporting Carvedilol, covering 415 formulations to 4 countries via 11 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 98+ countries, 529+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Carvedilol Export Data from Zydus Lifesciences Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Zydus Lifesciences Limited's Carvedilol exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Zydus Lifesciences Limited
Full Company Profile →
81 products · $346.3M total trade · 25 categories
Carvedilol Stats
Company Overview
Top Products by Zydus Lifesciences Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Zydus Lifesciences Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Carvedilol. For current shipment-level data, contact TransData Nexus.